RNAi Therapeutics in Autoimmune Disease

被引:25
|
作者
Pauley, Kaleb M. [1 ]
Cha, Seunghee [2 ]
机构
[1] Cedarville Univ, Dept Sci & Math, Cedarville, OH 45314 USA
[2] Univ Florida, Coll Dent, Dept Oral & Maxillofacial Diagnost Sci, 1600 SW Archer Rd, Gainesville, FL 32610 USA
来源
PHARMACEUTICALS | 2013年 / 6卷 / 03期
关键词
RNA interference; therapeutics; microRNA; small interfering RNA; autoimmune disease;
D O I
10.3390/ph6030287
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Since the discovery of RNA interference (RNAi), excitement has grown over its potential therapeutic uses. Targeting RNAi pathways provides a powerful tool to change biological processes post-transcriptionally in various health conditions such as cancer or autoimmune diseases. Optimum design of shRNA, siRNA, and miRNA enhances stability and specificity of RNAi-based approaches whereas it has to reduce or prevent undesirable immune responses or off-target effects. Recent advances in understanding pathogenesis of autoimmune diseases have allowed application of these tools in vitro as well as in vivo with some degree of success. Further research on the design and delivery of effectors of RNAi pathway and underlying molecular basis of RNAi would warrant practical use of RNAi-based therapeutics in human applications. This review will focus on the approaches used for current therapeutics and their applications in autoimmune diseases, including rheumatoid arthritis and Sjogren's syndrome.
引用
收藏
页码:287 / 294
页数:8
相关论文
共 50 条
  • [11] RNAi Therapeutics: State of the State
    Maraganore, John
    NUCLEIC ACID THERAPEUTICS, 2012, 22 (06) : A2 - A2
  • [12] Development of new RNAi therapeutics
    Liu, G.
    Wong-Staal, F.
    Li, Q. -X.
    HISTOLOGY AND HISTOPATHOLOGY, 2007, 22 (02) : 211 - 217
  • [13] RNAi therapeutics for CNS disorders
    Boudreau, Ryan L.
    Davidson, Beverly L.
    BRAIN RESEARCH, 2010, 1338 : 112 - 121
  • [14] RNAi therapeutics: An update on delivery
    Nguyen, Thu
    Menocal, Ellen M.
    Harborth, Jens
    Fruehauf, Johannes H.
    CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2008, 10 (02) : 158 - 167
  • [15] RNAi therapeutics in peripheral neuropathies
    Vita, G.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 971 - 971
  • [16] The Business of RNAi Therapeutics in 2012
    Haussecker, Dirk
    MOLECULAR THERAPY-NUCLEIC ACIDS, 2012, 1
  • [17] RNAi therapeutics for the lowering of cholesterol
    Fitzgerald, Kevin
    Frank-Kamenetsky, Maria
    Zimmermann, Tracy S.
    Horton, Jay
    Akinc, Akin
    Bramlage, Birgit
    Bumcrot, David
    Harborth, Jens
    John, Matthias
    Kotelianski, Victor
    Manoharan, Muthiah
    Maier, Martin
    Nechev, Lubomir
    Racie, Timothy
    Roehl, Ingo
    Seiffert, Stephan
    Shanmugam, Sumi
    Soutschelk, Jurgen
    Toudjarska, Ivanka
    Vormocher, Hans-Peter
    Zedalis, William
    CIRCULATION, 2007, 116 (16) : 105 - 105
  • [18] RNAi Therapeutics: The Teenage Years
    Perkel, Jeffrey M.
    BIOTECHNIQUES, 2012, 52 (06) : 355 - 357
  • [19] NOVARTIS EXITS RNAI THERAPEUTICS
    不详
    CHEMICAL & ENGINEERING NEWS, 2014, 92 (16) : 17 - 17
  • [20] Inhibitory receptor agonists: the future of autoimmune disease therapeutics?
    Grebinoski, Stephanie
    Vignali, Dario A. A.
    CURRENT OPINION IN IMMUNOLOGY, 2020, 67 : 1 - 9